Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320411
Status:
COMPLETED
Last Update Posted:
2019-01-31
First Post:
2006-05-01
Brief Title:
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Phase II Clinical Study of Lapatinib GW572016 in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study EGF104911 is designed to evaluate the efficacy and safety of lapatinib in patients with advanced or metastatic breast cancer Eligible subjects must have ErbB2 overexpressing tumors and are refractory to treatment with anthracycline taxanes and trastuzumab containing regimens The study data obtained from EGF104911 will be combined with the data from EGF100642 and integrated analysis will be carried out in order to enhance the credibility of the study results
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None